Caitlin Raymond: When We Talk About Plasma Exchange, Most Discussions Stop At What We’re Removing, But That’s Only Half The Story
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
”The Overlooked Half of the Exchange
When we talk about plasma exchange, most discussions stop at what we’re removing — antibodies, paraproteins, cytokines. But that’s only half the story.
Replacement fluid is the other half — and it quietly dictates safety, hemostasis, and recovery.
The right choice isn’t just technical; it’s clinical judgment in action.
In my latest blog post, I break down:
- When to use albumin vs. plasma, and why the timing matters
- How combination strategies (like 50:50 albumin–FFP) can balance practicality and bleeding risk
- Common myths and misconceptions — including why “albumin is always safer” isn’t true
- Real-world scenarios: TTP, transplant desensitization, AMR, and more
Read the full post.
Choosing the replacement fluid isn’t just following a protocol — it’s the art within the algorithm.
Because in apheresis, the machines may be automated, but judgment isn’t.”

Stay tuned for more posts on transfusion medicine featured in Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia